Compare JJSF & TRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JJSF | TRAX |
|---|---|---|
| Founded | 1971 | 2025 |
| Country | United States | United States |
| Employees | 1800 | N/A |
| Industry | Specialty Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.2B |
| IPO Year | 1995 | 2026 |
| Metric | JJSF | TRAX |
|---|---|---|
| Price | $85.40 | $45.73 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 12 |
| Target Price | ★ $110.50 | $74.17 |
| AVG Volume (30 Days) | 188.9K | ★ 1.1M |
| Earning Date | 11-18-2026 | 11-12-2026 |
| Dividend Yield | ★ 3.82% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.99 | N/A |
| Revenue | ★ $1,022,038,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.98 | N/A |
| P/E Ratio | $42.05 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $68.87 | $15.69 |
| 52 Week High | $98.63 | $49.91 |
| Indicator | JJSF | TRAX |
|---|---|---|
| Relative Strength Index (RSI) | 65.67 | 66.58 |
| Support Level | $77.64 | $40.72 |
| Resistance Level | $88.12 | $48.94 |
| Average True Range (ATR) | 2.13 | 3.08 |
| MACD | 0.58 | 1.10 |
| Stochastic Oscillator | 90.43 | 85.60 |
J&J Snack Foods Corp. manufactures snack foods and distributes frozen beverages, which it markets nationally to the foodservice and retail supermarket industries. The company's portfolio of frozen beverages, frozen novelties, and baked goods includes soft pretzels, frozen juice treats and desserts, stuffed sandwiches, churros, funnel cakes, cookies, and other snack foods and drinks. It operates through three segments: Food Service, which sells snacks, desserts, and baked goods at the point of sale; Retail Supermarkets, which sells frozen and prepackaged products to supermarkets; and Frozen Beverages, which sells frozen beverages under the ICEE, Slush Puppie, and Parrot Ice brands in the United States, Mexico, and Canada. The majority of revenue comes from the Food Service segment.
First Tracks Biotherapeutics Inc is a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases. Its clinical-stage pipeline includes rosnilimab, a selective pathogenic T cell depleter, for which it completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA), ANB033, a CD122 antagonist, in a Phase 1b trial for celiac disease (CeD) and eosinophilic esophagitis (EoE), and ANB101, a BDCA2 modulator, in a Phase 1a trial. The company operates in one reportable segment focused on research and development activities to deliver immunology therapeutics for autoimmune and inflammatory diseases.